• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物性心脏瓣膜病:更新。

Drug-induced valvular heart disease: an update.

机构信息

Service de pharmacologie clinique, hôpital Sud, CHU d'Amiens, avenue René-Laennec, Salouel, 80054 Amiens cedex 1, France.

出版信息

Arch Cardiovasc Dis. 2013 May;106(5):333-9. doi: 10.1016/j.acvd.2013.02.003. Epub 2013 Mar 22.

DOI:10.1016/j.acvd.2013.02.003
PMID:23769407
Abstract

Numerous reports have shown an unquestionable association between fibrotic valve disease and the following drugs: ergot alkaloids (such as methysergide and ergotamine), ergot-derived dopaminergic agonists (such as pergolide and cabergoline) and drugs metabolized into norfenfluramine (such as fenfluramine, dexfenfluramine and benfluorex). This review focuses on different aspects of drug-induced valvular heart disease: historical background; echocardiographic features; different drugs recognized as being responsible for valvular heart disease; and pathophysiology.

摘要

大量报告表明,纤维性瓣膜病与以下药物之间存在明确的关联:麦角生物碱(如麦角乙脲和麦角胺)、麦角衍生的多巴胺激动剂(如培高利特和卡麦角林)以及代谢为 norfenfluramine 的药物(如芬氟拉明、右芬氟拉明和苯氟雷司)。这篇综述重点介绍了药物性心脏瓣膜病的不同方面:历史背景;超声心动图特征;被认为可引起心脏瓣膜病的不同药物;以及病理生理学。

相似文献

1
Drug-induced valvular heart disease: an update.药物性心脏瓣膜病:更新。
Arch Cardiovasc Dis. 2013 May;106(5):333-9. doi: 10.1016/j.acvd.2013.02.003. Epub 2013 Mar 22.
2
[Drug-induced valve heart disease].[药物性瓣膜性心脏病]
Rev Prat. 2016 Oct;66(8):874-880.
3
Adverse effects of benfluorex on heart valves and pulmonary circulation.苯氟雷司对心脏瓣膜和肺循环的不良反应。
Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):679-86. doi: 10.1002/pds.3642. Epub 2014 May 10.
4
Impact of selective serotonin reuptake inhibitor therapy on heart valves in patients exposed to benfluorex: a multicentre study.暴露于苯氟雷司的患者中选择性 5-羟色胺再摄取抑制剂治疗对心瓣膜的影响:一项多中心研究。
Arch Cardiovasc Dis. 2013 Jun-Jul;106(6-7):349-56. doi: 10.1016/j.acvd.2013.04.006. Epub 2013 May 31.
5
Benfluorex and cardiac valve disease: long delay in publication.
Prescrire Int. 2013 Feb;22(135):47.
6
Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.瓣膜5-羟色胺5-HT(2B)受体在与芬氟拉明相关的心脏病中的可能作用。
Mol Pharmacol. 2000 Jan;57(1):75-81.
7
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.严重多瓣膜心脏病:麦角衍生物多巴胺激动剂的一种新并发症。
Mov Disord. 2004 Jun;19(6):656-62. doi: 10.1002/mds.20201.
8
Drug-induced fibrotic valvular heart disease.药物性纤维化瓣膜性心脏病
Lancet. 2009 Aug 15;374(9689):577-85. doi: 10.1016/S0140-6736(09)60252-X.
9
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.帕金森病中多巴胺激动剂治疗引发的心脏瓣膜纤维化反应。
Lancet Neurol. 2007 Sep;6(9):826-9. doi: 10.1016/S1474-4422(07)70218-1.
10
Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study.多巴胺受体激动剂治疗泌乳素瘤患者心脏瓣膜结构和功能的变化:一项 2 年随访研究。
Clin Endocrinol (Oxf). 2012 Jul;77(1):99-105. doi: 10.1111/j.1365-2265.2011.04326.x.

引用本文的文献

1
Current insights into the safety and adverse effects of methylphenidate in children, adolescents, and adults - narrative review.当前对哌甲酯在儿童、青少年及成人中的安全性和不良反应的见解——叙述性综述
Pharmacol Rep. 2025 Jul 22. doi: 10.1007/s43440-025-00763-0.
2
Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome.芬氟拉明在患有德雷维特综合征的儿童和成人中的长期安全性和有效性。
Epilepsia. 2025 Jun;66(6):1919-1932. doi: 10.1111/epi.18342. Epub 2025 Mar 12.
3
Risk of drug-induced pericardial effusion: a disproportionality analysis of the FAERS database.
药物性心包积液的风险:对FDA不良事件报告系统(FAERS)数据库的不成比例性分析
BMC Pharmacol Toxicol. 2025 Feb 7;26(1):27. doi: 10.1186/s40360-025-00867-6.
4
Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins.微量使用迷幻药与心脏纤维化和瓣膜病的风险:与已知的心脏毒素比较。
J Psychopharmacol. 2024 Mar;38(3):217-224. doi: 10.1177/02698811231225609. Epub 2024 Jan 12.
5
Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies.纳米技术在保护心肌细胞免受潜在心脏毒性药物损伤中的作用
Pharmaceutics. 2022 Dec 27;15(1):87. doi: 10.3390/pharmaceutics15010087.
6
The Therapeutic Potential of Carnosine as an Antidote against Drug-Induced Cardiotoxicity and Neurotoxicity: Focus on Nrf2 Pathway.肌肽作为一种对抗药物性心脏毒性和神经毒性的解毒剂的治疗潜力:聚焦 Nrf2 通路。
Molecules. 2022 Jul 12;27(14):4452. doi: 10.3390/molecules27144452.
7
Toward a broader view of mechanisms of drug cardiotoxicity.迈向对药物心脏毒性机制更广泛的认识。
Cell Rep Med. 2021 Mar 16;2(3):100216. doi: 10.1016/j.xcrm.2021.100216.
8
Advanced Imaging Modalities to Monitor for Cardiotoxicity.先进的影像学方法监测心脏毒性。
Curr Treat Options Oncol. 2019 Aug 8;20(9):73. doi: 10.1007/s11864-019-0672-z.
9
Drug-associated valvular heart diseases and serotonin-related pathways: a meta-analysis.药物相关性心脏瓣膜病与 5-羟色胺相关通路:荟萃分析
Heart. 2019 Aug;105(15):1140-1148. doi: 10.1136/heartjnl-2018-314403. Epub 2019 May 25.
10
Ergot alkaloid exposure during gestation alters. I. Maternal characteristics and placental development of pregnant ewes1.妊娠期间麦角生物碱暴露会改变。I. 怀孕母羊的母体特征和胎盘发育 1。
J Anim Sci. 2019 Apr 3;97(4):1874-1890. doi: 10.1093/jas/skz068.